Tencent Music Entertainment Group (NYSE: TME): A Leader in Digital Innovation and AI Investment

By Patricia Miller

Mar 19, 2025

3 min read

Tencent reports strong FY2024 earnings with robust revenue growth and increased AI investment, indicating potential stock rise.

Tencent Music TME

Tencent Holdings Limited, a leading internet and technology company based in China, has released its financial results for FY2024 and Q4 2024. The company achieved significant revenue and profit growth while stepping up investments in AI development.

  • High Revenue Growth: Tencent reported an 8% year-on-year increase in total revenues, reflecting strong demand and business expansion.

  • Increased Profit Margins: The non-IFRS (Non-International Financial Reporting Standards) operating profit grew 24% year-on-year, leading to greater profitability for the company.

  • AI Investment Boost: The focus on AI technology is expected to drive future revenue and enhance user engagement across platforms.

  • Shareholder Returns: Tencent repurchased a substantial amount of its shares, indicating strong confidence in its future performance and commitment to returning value to shareholders.

  • Market Leadership: The company's platforms like Weixin and QQ maintain their competitive edge, indicating resilience in a competitive market.

#About the Company

Tencent Holdings Limited is a major player in the internet and technology sector in China, offering services that connect users with digital content and social networks. Tencent operates popular platforms such as Weixin, QQ, and Tencent Music, along with a range of online games and advertising services.

Tencent Music Entertainment (NYSE: TME) is a subsidiary of Tencent Holdings, operating as its music streaming and entertainment arm. It was spun off and listed on the New York Stock Exchange (NYSE: TME) in 2018 but remains majority-owned by Tencent.

As of March 19, 2025, the TME market cap is approximately $25.62B. The company has shown strong financial performance with significant revenue growth in FY2024.

#Growth Drivers and Market Opportunities

Tencent is strategically positioned to benefit from the growing demand for AI-based solutions and digital services. AI is a key focus for Tencent, with capital expenditure increasing in 2025. The increase in AI investment aims to enhance advertising effectiveness and game longevity, potentially raising stock prices. Additional opportunities stem from expanding e-commerce and financial technology services. Tencent's gaming portfolio diversification also positions it favorably for future growth, allowing it to capture new audiences and deepen existing user engagement.

#Risks and Challenges

Tencent grapples with regulatory scrutiny in China, which may impact its operations and market strategy. The potential downturn in consumer spending and geopolitical tensions could also pose risks to its growth trajectory. Additionally, competition in the tech sector is fierce, necessitating ongoing innovation and adjustments in strategy.

Tencent continues to face significant competition from Alibaba, ByteDance, and Baidu, all of whom are aggressively expanding AI and digital services.

#What's Next: Catalysts and Risks

Analysts maintain a cautiously optimistic outlook for Tencent. While the stock has potential due to its strategic focus on AI and digital services, investors should remain alert to regulatory changes and competitive pressures. Upcoming product launches and earnings reports could prove pivotal in shaping the stock's future performance.

#Relevant ETFs

  • Global X China Technology ETF (CHIQ)

  • Invesco China Technology ETF (CQQQ)

  • KraneShares CSI China Internet ETF (KWEB)

  • iShares China Large-Cap ETF (FXI)

  • Invesco Golden Dragon China ETF (PGJ)

  • SPDR S&P China ETF (GXC)

#A Breakthrough in Skin Cancer Treatment?

Medical science is evolving, and new approaches are emerging that could change the way certain conditions are treated. A biotech company is developing a non-invasive therapy designed for skin cancer, potentially offering a new alternative to traditional treatments.

With a leadership team that includes industry veterans and a structured clinical trial process underway, this company is making progress in an area of significant medical need.

Curious about these latest developments? See what’s happening in biotech.

Important Notice And Disclaimer

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of ValueTheMarkets.com, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of ValueTheMarkets.com, has not been paid for the production of this piece by the company or companies mentioned above.